Galmed Pharmaceuticals (GLMD) News Today → A ‘DeFi Summer’ Projected! (From Crypto 101 Media) (Ad) Free GLMD Stock Alerts $0.38 -0.02 (-4.96%) (As of 05/15/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 10, 2024 | americanbankingnews.comGalmed Pharmaceuticals (NASDAQ:GLMD) Share Price Passes Below 200-Day Moving Average of $0.38May 10, 2024 | americanbankingnews.comGalmed Pharmaceuticals (NASDAQ:GLMD) Receives New Coverage from Analysts at StockNews.comApril 13, 2024 | fool.comGalmed Pharmaceuticals (NASDAQ: GLMD)April 10, 2024 | investorplace.comWall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for April 2024April 4, 2024 | prnewswire.comGalmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023March 15, 2024 | markets.businessinsider.comGalmed Granted European Patent For Use Of Aramchol-Resmetirom To Treat NASH/MASH, Liver FibrosisMarch 15, 2024 | prnewswire.comGalmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver FibrosisFebruary 13, 2024 | uk.finance.yahoo.comGalmed Pharmaceuticals Ltd (GPH.BE)January 3, 2024 | uk.finance.yahoo.comGalmed Pharmaceuticals Ltd. (GPH.F)November 20, 2023 | finance.yahoo.comGalmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a StudyNovember 4, 2023 | morningstar.comGalmed Pharmaceuticals Ltd GLMDSeptember 26, 2023 | finance.yahoo.comGalmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal FibrosisAugust 3, 2023 | nasdaq.comGalmed Pharmaceuticals (GLMD) Price Target Increased by 300.00% to 4.08July 14, 2023 | marketwatch.comGalmed Pharma Shares Drop 30% After Public Offering PricesJuly 14, 2023 | seekingalpha.comGalmed shares slump on pricing discounted stock and warrants offeringJuly 14, 2023 | finance.yahoo.comGalmed Pharmaceuticals Announces Pricing of $7 Million Public OfferingJuly 14, 2023 | marketbeat.comTrading was temporarily halted for "GLMD" at 09:07 AM with a stated reason of "LULD pause."July 13, 2023 | investorplace.comWhy Is Galmed Pharmaceuticals (GLMD) Stock Moving Today?July 12, 2023 | marketbeat.comTrading was temporarily halted for "GLMD" at 12:07 PM with a stated reason of "LULD pause." Trading set to resume at 12:07 PM. July 12, 2023 | marketbeat.comTrading was temporarily halted for "GLMD" at 12:07 PM with a stated reason of "LULD pause."July 12, 2023 | marketbeat.comTrading was temporarily halted for "GLMD" at 12:07 PM with a stated reason of "LULD pause."July 10, 2023 | finance.yahoo.comGalmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSCJuly 3, 2023 | bizjournals.comMadrigal begins process seeking OK for multibillion-dollar — yet elusive — NASH drugJune 3, 2023 | benzinga.comGalmed Pharmaceuticals Stock (NASDAQ:GLMD), Insider Trading ActivityJune 1, 2023 | finanznachrichten.deGalmed Pharmaceuticals Ltd.: Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent DevelopmentsJune 1, 2023 | msn.comRecap: Galmed Pharmaceuticals Q1 EarningsJune 1, 2023 | finance.yahoo.comGalmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent DevelopmentsMay 17, 2023 | thestreet.comWhy Galmed Pharmaceuticals (GLMD) Stock Is Surging TodayMay 11, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Galmed Pharmaceuticals (GLMD) and Haemonetics (HAE)May 9, 2023 | finance.yahoo.comGalmed Announces Initiation of a Clinical Development Program to Evaluate Aramchol meglumine for the Treatment of Primary Sclerosing Cholangitis (PSC)May 5, 2023 | msn.comWhy Is Galmed Pharmaceuticals (GLMD) Stock Up 37% Today?May 4, 2023 | finance.yahoo.comGalmed Pharmaceuticals forms a Strategic Partnership with OnKaiMarch 29, 2023 | finance.yahoo.comGalmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022February 17, 2023 | seekingalpha.comGLMD Galmed Pharmaceuticals Ltd.February 8, 2023 | finance.yahoo.comGalmed Announces Issuance of New Composition of Matter Patent for Aramchol meglumine SaltJanuary 6, 2023 | finance.yahoo.comCan Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth?January 4, 2023 | marketwatch.comGalmed Pharmaceuticals Shares Up 9.2% on Data From Liver Treatment Aramchol StudyJanuary 4, 2023 | finance.yahoo.comGalmed reports results from the Open-Label part of the ARMOR study showing improvements in histology, imaging, and biomarkers with AramcholDecember 14, 2022 | finance.yahoo.comGalmed Pharmaceuticals Ltd. (NASDAQ: GLMD) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price RequirementSeptember 14, 2022 | finance.yahoo.comGalmed Pharmaceuticals (GLMD) Moves to Buy: Rationale Behind the UpgradeAugust 4, 2022 | finance.yahoo.comGalmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial ResultsJuly 7, 2022 | finance.yahoo.comGalmed's Aramchol Shows Anti-Fibrotic Effects In Lung Fibrosis Animal ModelJuly 7, 2022 | nasdaq.comGalmed: New Data Reinforces Expansion Of Aramchol's Clinical Development To Additional IndicationsJuly 7, 2022 | finance.yahoo.comGalmed Reports Significant Anti-Fibrotic Effects of Aramchol in a Lung Fibrosis ModelJune 17, 2022 | finance.yahoo.comGalmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price NotificationMay 25, 2022 | benzinga.comGalmed Pharmaceuticals (NASDAQ:GLMD), Analyst Ratings, Price Targets, PredictionsMay 18, 2022 | seekingalpha.comGalmed Pharmaceuticals shares fall after downgrade by Raymond James analystMay 17, 2022 | finance.yahoo.comGalmed updates business and clinical development strategy to better leverage Aramchol's anti-fibrotic effectsMay 17, 2022 | finance.yahoo.comGalmed Pharmaceuticals Reports First Quarter 2022 Financial ResultsMay 3, 2022 | marketwatch.comGalmed Pharmaceuticals Shares Down 16% Get Galmed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for GLMD and its competitors with MarketBeat's FREE daily newsletter. Email Address A ‘DeFi Summer’ Projected! (Ad)Top analysts are predicting DeFi coins to see massive gains in the coming months… During this dubbed ‘DeFi Summer…’ A coin that has been called the “DeFi pioneer” is poised to shoot up 3-7x! Just click here to learn how you can access this coin right now. GLMD Media Mentions By Week GLMD Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GLMD News Sentiment▼0.390.54▲Average Medical News Sentiment GLMD News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GLMD Articles This Week▼40▲GLMD Articles Average Week Get Galmed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for GLMD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: BPTH News Today CMND News Today PXMD News Today DRMA News Today SLRX News Today QLGN News Today CNSP News Today CWBR News Today SXTP News Today ALLR News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GLMD) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldTop 5 AI Stocks to Buy for 2024Market Moving TrendsThis unknown company solves the biggest issue with AIManward PressShocking $16T Elon Musk Crypto LeakCrypto 101 MediaWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsCharles Payne Demystifies OptionsUnstoppable Prosperity Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galmed Pharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.